Resources from the same session
Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
Presenter: Corey Langer
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
Presenter: Fabrice Barlesi
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator’s choice (IC): CheckMate 141
Presenter: Kevin Harrington
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Presenter: Martin Reck
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
Invited discussant LBA46_PR and LBA8_PR
Presenter: Jean-Charles Soria
Session: Presidential Symposium 2
Resources:
Presentation
Invited discussant LBA4_PR
Presenter: Anthony Tak Cheung Chan
Session: Presidential Symposium 2
Resources:
Presentation
CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Presenter: Mark Socinski
Session: Presidential Symposium 2
Resources:
Abstract
Presentation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.